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Cell therapy may be regarded as a feasible alternative to whole organ transplantation to treat end-stage liver diseases. Human liver
stem cells (HLSCs) are a population of cells easily obtainable and expandable from a human adult liver biopsy. HLSCs share with
mesenchymal stromal cells the same phenotype, gene expression profile, and differentiation capabilities. In addition, HLSCs show a
specific commitment to the hepatic phenotype. Injection of HLSCs into immunodeficient mice fed with a methionine-choline-
deficient diet to induce nonalcoholic steatohepatitis ameliorates liver function and morphology. In particular, HLSC treatment
induced a reduction of liver fibrosis and inflammation at morphological and molecular levels. Moreover, HLSCs were able to
persist for up to 3 weeks after the injection. In conclusion, HLSCs have healing effects in a model of chronic liver disease.
1. Introduction
Nonalcoholic fatty liver disease is a cause of chronic liver dis-
ease worldwide. A fraction of patients with nonalcoholic fatty
liver disease (about 30%) develop nonalcoholic steatohepati-
tis (NASH), characterized by liver fibrosis and inflammation
eventually leading to cirrhosis, hepatocellular carcinoma, and
other liver-related complications. The prevalence of NASH
in Western countries with nonalcoholic fatty liver disease is
20-30% and is steadily increasing in parallel with the rising
prevalence of obesity and insulin resistance [1, 2].
Liver transplantation is currently the standard therapy
for end-stage liver disease including NASH. In addition, cir-
rhosis leading to NASH is the second most common indica-
tion for liver transplantation in the USA. However, high cost,
lifelong immunosuppressive agents, and a shortage of organ
donors limit the availability of such treatment [2, 3]. Lately,
cell-based therapy is emerging as a possible alternative for
the treatment of NASH manifestations. In particular, bone
marrow-derived mesenchymal stromal cells (MSCs), which
have exhibited therapeutic efficacy in experimental models
of NASH [4], show functional engraftment of transplanted
cells [5, 6]. In addition, hepatocytes derived by differentiating
induced pluripotent stem cells have been successfully used
for the treatment of NASH in mice [7].
Herrera et al. isolated and characterized a population of
multipotent stem cells from a human liver biopsy which
exhibited a high proliferative capacity [8]. This population
of cells currently known as human liver stem cells (HLSCs)
express many surface markers in common with MSCs
(CD73, CD29, CD105, CD90, and CD44), various stem cell
and embryonic markers (Nanog, Oct3/4, Sox2, Musashi,
SSEA4, and Pax2), and markers specific to hepatic cells
(albumin, cytokeratin-8, and cytokeratin-18) [8]. HLSCs,
similar to MSCs, also exhibit immunomodulatory properties
[9]. Furthermore, they are able to differentiate into osteo-
cytes, endothelial cells, and functional hepatocytes, as well
as form islet-like structures [8, 10, 11]. When injected in
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different experimental models of acute liver injury, HLSCs
have not only improved liver function and morphology
but also engrafted into injured livers [8, 12]. Moreover,
HLSCs are also able to improve the recovery of injury in
other organs, such as the kidneys [13]. In this work, we eval-
uated whether HLSCs, obtained and expanded in Good
Manufacturing Practice (GMP) conditions, may offer an
alternative option for the treatment of NASH-associated
fibrosis and inflammation.
2. Materials and Methods
2.1. Isolation and Culture of HLSCs in GMP Conditions. A
HLSC-master cell bank (MCB) was generated by Anemocyte
International S.v.I. (Gerenzano, Italy) from a 10-15 mm liver
fragment obtained from a liver donor, according to standard
criteria of Centro Nazionale Trapianti, as described [8]. The
liver fragment was digested in GoodManufacturing Practice-
(GMP-) grade collagenase (NBI, 0.6 mg/ml) and neutral pro-
tease (NBI, 0.73 mg/ml) for 30 minutes at 37°C. The liver cell
suspension, obtained from enzymatic digestion, was washed
(400 g for 10 minutes) and cultured (2 5 × 105/ml in a T75
flask with a 10 ml/flask) in the presence of a GMP medium,
composed of minimal essential medium (α-MEM, Lonza,
Basel, Switzerland) supplemented with 10% fetal calf serum
(Gibco, Cambrex), 10 ng/ml of human recombinant epider-
mal growth factor (Miltenyi Biotec, Bergisch Gladbach,
Germany), 10 ng/ml of human recombinant fibroblast
growth factor basic (Miltenyi Biotec, Bergisch Gladbach,
Germany), 2 nM of L-glutamine (Lonza), and 100 U/ml of
penicillin/streptomycin (from Sigma-Aldrich, St. Louis,
MO, USA) and maintained in a humidified 5% CO2 incuba-
tor at 37°C. HLSCs, obtained from the liver cell suspension
after 2 weeks of culture, were seeded at the density of 2 5 ×
105 cells per flask (T75) in the same culture medium. Once
the cells reached up to about 80% of confluency, they were
harvested and centrifuged at 400 g for 5 minutes and used
for experimental purposes. All reagents used were suitable
for clinical use and produced in conditions analogous to
European and Italian GMP.
Routine characterization of HLSCs was performed by
cytofluorimetric analyses using the Guava easyCyte Flow
Cytometer (Millipore, Billerica, MA, USA) and analysed with
InCyte software for the expression of typical MSC (CD29,
CD73, and CD105 all from Miltenyi Biotec) and hepatic
(Albumin, LSBio, LifeSpan BioSciences, Seattle, Washington)
markers. Indirect immunofluorescence was performed on
HLSCs cultured on chamber slides (Nalge Nunc Interna-
tional, Rochester, NY), fixed in 4% paraformaldehyde con-
taining 2% sucrose, and permeabilized with HEPES Triton
X-100 buffer. The following monoclonal antibodies (Ab)
were used: anti-α-fetoprotein, anti-albumin (R&D Systems,
Abington, UK), anti-α-smooth muscle actin (α-SMA) (Dako
Denmark A/S), anti-cytokeratin-18 (Chemicon International,
Temecula, CA,), anti-cytokeratin-8, and anti-cytokeratin-
19 (Santa Cruz Biotechnology, CA, USA). Anti-vimentin
(Sigma-Aldrich), anti-nestin, anti-Musashi, anti-Nanog,
anti-Oct3/4, anti-SSEA4, and anti-Sox2 rabbit polyclonal anti-
bodies (Abcam, Cambridge, UK) were used. Omission of the
primary antibodies was used as the control where appropriate.
Alexa Fluor 488 or Texas Red anti-rabbit IgG or anti-mouse
IgG (Molecular Probes, Leiden, Netherlands) was used as
secondary Ab. Confocal microscopy analysis was performed
using a Zeiss LSM 5 Pascal Model Confocal Microscope
(Zeiss International, Jena, Germany). Hoechst 33258 dye
(Sigma-Aldrich) was added for nuclear staining.
2.2. Culture of MSCs. Bone marrow MSCs were obtained
from Lonza and cultured and characterized as previously
described [14]. The cell preparations used were positive for
the typical MSC markers (CD105, CD29, CD73, CD44, and
CD90) and had the ability to differentiate into adipogenic
and osteogenic lineages (not shown).
2.3. Telomere Length. DNA from HLSCs at different passages
(6 to 17 passages) was extracted with the DNeasy Blood &
Tissue Kit (QIAGEN) according to the manufacturer’s pro-
tocol. Telomere length was evaluated by real-time PCR with
the Absolute Human Telomere Length Quantification qPCR
Assay Kit (ScienCell Research Laboratories, Carlsbad, CA,
USA) following the manufacturer’s protocol.
2.4. Human Mesenchymal Stem Cell PCR array. RNA was
extracted by TRIzol (Ambion) from MSCs (Lonza) and
HLSCs at different culture passages. Samples were retrotran-
scribed with the RT2 First Strand Kit and gene expression was
analysed by RT2 Profiler™ PCR Array Human Mesenchymal
Stem Cells (PAHS-082Z, QIAGEN) following the manufac-
turer’s protocol.
2.5. In Vivo Model. Animal studies were conducted in accor-
dance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. All procedures were
approved by the Italian Health Ministry (authorization num-
ber: 419/2016-PR).
NASH was induced by continuous feeding of mice with
methionine-choline-deficient diet (MCDD), as previously
reported [5, 7]. MCDD induces fast, reproducible, and severe
liver damage. Moreover, MCDD activates similar mecha-
nisms of fibrosis and inflammation as in human NASH pro-
gression and so is ideal for studying strategies to inhibit these
processes [15].
Severe Combined Immunodeficient (SCID, Charles
River Laboratories, Wilmington, MA, USA) male mice, 10
weeks old, were accustomed to a MCDD (MP Biomedicals,
Eschwege, Germany) by feeding a mixture of standard and
MCD chow for 1 week. Thereafter, the full MCD chow was
given. HLSCs (1 5 × 106) fromMCB, at passages 7 to 9 of cul-
tures, were injected intravenously (tail vein) at different time
points after the beginning of MCDD (Figure 1), at weeks 1
(Group 1: n = 11), 2 (Group 2: n = 9), or 3 (Group 3: n = 9).
The NASH control group was injected with the vehicle alone
(PBS) (n = 5/week). Control animals (n = 12) were fed with
standard diet. For the dose/response study, NASH mice were
injected at week 2 with different doses of HLSCs (n = 6 for
0 5 × 106 and n = 8 for 3 0 × 106). All animals were sacrificed
at week 4, and the blood and liver were recovered for bio-
chemical, histological, and molecular analyses.
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2.6. Histological Analyses. Liver morphology was evaluated
through formalin-fixed paraffin-embedded tissue staining.
Briefly, 5 μm thick paraffin liver sections were routinely
stained, for microscopic evaluation, with hematoxylin and
eosin (H&E, Merck) or Sirius Red for collagen.
Liver fibrosis was quantified by measuring collagenous
fibrotic areas stained in red (sections stained with Sirius
Red) in 10 random fields/section from images taken at a
magnification of 400x, using multiphase image analyses with
ImageJ software version 1.49s [16]. The surface area occupied
by steatosis vacuoles was quantified in 10 random fields/sec-
tion from images taken at a magnification of 200x, using
multiphase image analyses with ImageJ software. Immuno-
histochemistry for the detection of proliferating hepatocytes
was performed on paraffin liver sections. Briefly, paraffin sec-
tions were subjected to antigen retrieval, followed by block-
ing and labelling with 1 : 400 of anti-PCNA (Santa Cruz
Biotechnology). Immunoperoxidase staining was then per-
formed using a 1 : 300 dilution of the secondary HRP anti-
body (Pierce). Scoring for PCNA-positive cells was carried
out by counting the number of positive nuclei per HPF
(high-power field, 40x) in 10 randomly chosen sections.
Immunofluorescence was performed on 5 μm thick cryo-
stat sections. Sections were stained with mouse anti-CD45
(Biorbyt, San Francisco, CA, USA), mouse anti-S100A4 (fibro-
blast-specific protein 1 (FSP1), Abcam, Cambridge, MA,
USA), or rabbit anti-human leukocyte antigen (HLA) class I
rabbit (Santa Cruz Biotechnology) antibodies for 2 hours at
4°C. Rabbit anti-mouse FITC or anti-rabbit FITC (Molecular
Probes) was used as secondary antibodies. Hoechst 33258
dye (Sigma-Aldrich) was added for nuclear staining. Confocal
microscopy analysis was performed using a Zeiss LSM 5
Pascal Model Confocal Microscope (Zeiss International).
2.7. Quantitative Real-Time PCR. Total RNA was extracted
from the liver tissue of the control or NASH mice treated
with or without HLSCs using TRIzol™ reagent (Ambion,
Thermo Fisher) according to the product’s instruction.
Briefly, mouse hepatic tissue was resuspended in 1 ml of TRI-
zol™ solution and homogenised in a Bullet Blender instru-
ment (Next Advance Inc., New York, NY, USA) at a speed
of 8 for 3 min using 0.5 mm size zirconium oxide beads
and centrifuged at 12,000 g for 15 min at 4°C. Supernatant
from homogenised tissue was used to isolate RNA, as men-
tioned above, which was quantified spectrophotometrically
(NanoDrop ND-2000, Thermo Fisher Scientific). For gene
expression analysis, quantitative real-time PCR was per-
formed as described previously [17]. Briefly, first-strand
cDNA was synthesised from 200 ng of total RNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). qRT-PCR was performed using
the StepOnePlus RT-PCR machine (Applied Biosystems,
Foster City, CA) in a 20 μl reaction mixture containing 5
ng or 10 ng of cDNA template (according to tested gene
expression analysis), the sequence-specific oligonucleotide
primers (purchased from MWG Biotech, Eurofins Scientific,
Brussels, Belgium), and the Power SYBR Green PCR Master
Mix (Applied Biosystems). The GAPDH or TBP gene was
used as a housekeeping gene to normalize RNA inputs. Fold
change expressions with respect to control were calculated
for all samples using the ΔΔCt method. The primers used
for qRT-PCR are reported in Table 1.
2.8. Whole Genome DNA Analysis. Whole genome DNA
was extracted from the frozen tissues of MCDD-fed mice
treated or not with HLSCs at different time points using
a DNA isolation kit (QIAGEN). Following quantification,
200 ng of DNA was amplified through PCR for human-
specific DNA repeat α-satellite chromosome 17 (1171 bp
fragment) (hu-α-sat-Ch-17) using the following primers: for-
ward 5′-ACACTCTTTTTGCAGGATCTA-3′ and reverse
5′-AGCAATGTGAAACTCTGGGA-3′ [18]. The PCR sam-
ples were then analysed using agarose gel electrophoresis and
analysed using the Gel Doc system (Bio-Rad). DNA isolated
from HLSCs was used as a positive control and water as a
negative control.
Week 1 Week 2 Week 3
Endpoint
Week 4T0
MCD + standard diet MCD diet
NASH group: vehicle alone
Group 1: HLSC 1.5 × 106
NASH group: vehicle alone
Group 2: HLSC 1.5 × 106
NASH group: vehicle alone
Group 3: HLSC 1.5 × 106
Figure 1: Schematic overview of the experimental design to test HLSCs in MCDD-fed mice, showing the week of MCDD and HLSCs or
vehicle administration.
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2.9. Statistical Analysis. Data analyses were performed using
GraphPad Prism 6.0. Results are expressed as mean ± SD.
Statistical analyses were performed by employing analysis
of variance (ANOVA) with the Newman–Keuls test. A
p value of <0.05 was considered significant.
3. Results
3.1. Characterization of HLSCs Obtained and Cultivated in
GMP Conditions. The HLSC-master cell bank was charac-
terized as previously reported [8]. Immunocytochemistry
revealed HLSCs to be 100% positive for the hepatocyte pre-
cursor marker α-fetoprotein, mature hepatocyte protein
(albumin), the stem cell markers vimentin and nestin, and
embryonic stem cell markers (Oct3/4, Nanog, SSEA4, Sox2,
and Musashi1). HLSCs were also positive for cytokeratin-8
and cytokeratin-18 at about 20-30% (Figure 2(a)) and nega-
tive for the hepatic oval cell marker cytokeratin-19. HLSCs
did not express α-Sma (Figure 2(c)). Flow cytometric analysis
revealed that HLSCs were positive for several MSC markers
such as CD29, CD73, and CD105 and further confirmed
the expression of albumin (Figure 2(b)).
Telomere length is a marker of cellular senescence
[19]. For this reason, we evaluated the telomere length dur-
ing expansion of HLSCs from P6 to P17 (Figure 2(d)).
Despite an initial reduction, HLSC telomere length remained
stable from P7 to P17, with a mean value of 239 ± 57 kb,
indicating that HLSCs remained stable for over seventeen
culture passages.
Since HLSCs andMSCs share the same phenotype, differ-
entiation, and immunomodulatory properties, we decided
to compare the gene expression profile of HLSCs with that
of bone marrow-derived MSCs, using a specific MSC PCR
array. The expression of 84 key genes involved in self-
renewal and specific-MSC-differentiation capacities was
evaluated. HLSCs showed a very similar gene expression
profile to MSCs, on comparing the two cell populations at
passage 3. Only 13 genes, out of 84, were differentially
expressed in HLSCs with respect to MSCs (Figures 3(a) and
3(b)). In addition, the gene expression profile confirmed the
presence of specific hepatic markers, such as hepatocyte
growth factor (HGF) (Figures 3(a)–3(c)) and cytokeratin-18
(Figure 3(d)) in HLSCs. Moreover, a comparison between
HLSCs at passage 3 of the culture and HLSCs at passages
6 and 12 revealed a similarity between the gene expression
profile up to 12 culture passages, indicating the stability of
HLSCs in vitro (Figures 3(e) and 3(f)).
3.2. HLSCs Improve Liver Function and Morphology. To
evaluate the potential therapeutic ability of HLSCs in a
mouse model of NASH, we induced NASH by feeding SCID
mice with a MCDD for 4 weeks. During this period, we
assessed the efficacy of HLSC administration at different time
points (Figure 1). Mice on a MCDD had an increase of ala-
nine aminotransferase (ALT) and aspartate aminotransferase
(AST) in the plasma, while albumin levels decreased
(Figure 4). However, on injecting HLSCs at different time
points of MCDD, a significant decrease in the plasma levels
of ALT and AST was observed (Figure 4). In addition, serum
albumin levels were restored to healthy control levels by
HLSCs injected at weeks 1 and 2 (Figure 4).
One of the main hallmarks of NASH is liver fibrosis. His-
tologically, fibrosis was highlighted through Sirius Red stain-
ing of collagen, which was increased in MCDD-fed mice,
primarily in both perivenous and periportal areas of the liver
(Figure 5(a)). Compared to vehicle-treated animals, MCDD-
fed mice that received HLSCs at week 1, 2, or 3 showed a
significant reduction in fibrosis (Figures 5(a) and 5(b)).
Collagen is secreted by activated stellate cells, which are char-
acterized by the expression of α-SMA [20]. mRNA expres-
sion levels of Col1a1 (collagen I) and α-Sma were elevated
in the livers of MCDD-fed mice, compared to mice fed with
the standard diet (Figure 5(e)). The mRNA levels of α-Sma
and Col1a1 decreased in NASH mice treated with HLSCs at
different time points with a statistically significant reduction
observed in NASH mice injected at week 2 (Figure 5(e)).
Moreover, the mRNA expression level of the fibrogenic
factor Tgf-β was significantly reduced in MCDD-fed mice
injected with HLSCs at the different time points tested
(Figure 5(e)).
Transplantation of HLSC also attenuated steatosis,
but the reduction did not reach statistical significance
(Figure 5(c)). Moreover, an injection of HLSCs at week 1 of
MCDD induced an increase in the proliferation of hepato-
cytes as inferred by PCNA staining (Figure 5(d)).
Table 1: RT-PCR-specific primers.
Gene Sense (5′→3′) Antisense (5′→3′)
m-Collagen type I ATCTCCCTGGTGCTGATGGAC ACCTTGTTTGCCAGGTTCAC
m-TGF-beta1 GCAACAATTCCTGGCGTTACC CGAAAGCCCTGTATTCCGTCT
m-Alpha-smooth muscle actin CATCTCCGAAGTCCAGCACA GACGCACCACTGAACCCTAA
m-IL-1beta CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA
m-INF-gamma GAGCCAGATTATCTCTTTCATCC GTTGTTGACCTCAAACTTGG
m-TNF-alpha CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
m-GADPH TGTCAAGCTCATTTCCTGGTATGA TACTCCTTGGAGGCCATGT
HGF CACACAGGTATATTTGCTGGATGATAA GGGACACAAGGTATAAATTGTTTTGG
CK-18 TGGTACTCTCCTCAATCTGTCG CTCTGGATTGACTGTGGAAGT
TBP TGTGCACAGGACCCAAGAGT ATGTGCACAGGACCCAAGAGT
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To define the optimal dose of HLSCs to obtain a signifi-
cant improvement in liver function and morphology, a
dose/response study was performed whereby different con-
centrations of HLSCs were injected at week 2 of MCDD.
All the cell doses tested (0.5, 1.5, and 3 0 × 106) induced a
reduction in fibrosis (Figure 6(a)). Furthermore, serum
markers of the liver function indicated that all the cell doses
tested showed significantly normalized ALT levels. However,
AST and albumin levels were improved significantly only
with the dose of 1 5 × 106 cells (Figures 6(c)–6(e)). In the case
of blood urea nitrogen levels in the plasma, only the higher
dose tested induced a significant reduction (Figure 6(f)).
3.3. HLSCs Reduce Liver Inflammation. Along with fibrosis,
NASH is also associated with liver inflammation [4, 6]. Liver
tissue of MCDD-fed mice displayed a significant upregula-
tion in the mRNA levels of proinflammatory cytokines such
as Tnf-α, Il-1β, and Ifn-γ (Figure 7(a)). However, injection
with HLSCs induced a reduction in mRNA expression levels
of both Il-1β and Ifn-γ indicating an anti-inflammatory effect
of HLSCs (Figure 7(a)).
To complete the evaluation of the inflammatory status of
the liver tissue of MCDD-fed mice injected with or without
HLSCs, we evaluated the presence of inflammatory cells,
using specific markers, such as CD45 (common leukocyte
antigen) and FSP1 (fibroblast-specific protein 1), that recog-
nize a specific subset of inflammatory macrophages during
liver injury, fibrosis, and cancer [21]. CD45+ cells and/or
FSP1+ cells were present in the livers of MCDD-fed mice.
On the other hand, no inflammatory infiltrates were
observed in mice injected with HLSCs at different time points
(Figures 7(b) and 7(c)).
3.4. HLSC Engraftment. The presence of HLSCs (human
cells) injected in MCDD-fed mice at different time points
was evaluated through the analysis of hu-α-sat-Ch-17 in
mouse DNA. We found that hu-α-sat-Ch-17 was detectable
in all NASH (9 out of 9) mice injected with HLSCs at week
3 (sacrificed at week 4), in 6 out of 9 NASH mice injected
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Figure 2: Characterization of HLSC-master cell bank. (a, c) Representative confocal micrographs showing the expression of several hepatic,
mesenchymal, and embryonic stem cell markers in HLSCs (original magnification at ×400). Three experiments were performed with similar
results of HLSCs at passage 6 of the culture. (b) Representative FACS analyses of HLSCs showing the expression of albumin, CD29, CD73, and
CD105 (red histogram). Yellow histograms represent isotypic control. Three experiments were performed with similar results of HLSCs at
passage 6 of the culture. (d) Telomere length of HLSCs was measured using the Absolute Human Telomere Length Quantification qPCR
Assay Kit. A single copy reference (SCR) primer set recognizes and amplifies a 100 bp long region on human chromosome 17 and serves
as reference for data normalization. The reference genomic DNA sample with known telomere length (Ctrl) serves as a reference for
calculating the telomere length of MCB.
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Figure 3: Gene expression profile of HLSCs. (a) Scatter plot showing the comparison of gene expression, screened by humanMSC PCR array
(PAHS-082Z) which includes genes that define the stemness, pluripotency, and self-renewal characteristics of MSCs and HLSCs at passage 3.
The array does not include epithelial markers. Red dots represent genes more expressed by HLSCs, while blue dots represent genes more
expressed by MSCs. Black dots are genes not differentially expressed. (b) Relative quantification (RQ) of genes more expressed by HLSCs
with respect to MSCs. (c, d) Real-time PCR of hepatocyte growth factor (HGF) and cytokeratin-18 (CK18) expression in HLSCs
compared with MSCs. Data are expressed as relative quantification using the ΔΔCt method. Normalization was made using TBP as a
housekeeping gene. ANOVA with the Newman-Keuls multicomparison test was performed; ∗p < 0 05 HLSCs versus MSCs. (e, f) Scatter
plots comparing the gene expression of HLSCs at passage 3 versus passage 6 (e) and passage 12 (f). Red dots represent genes more
expressed by HLSCs at passage 6 or 12, while blue dots represent genes more expressed by HLSCs at passage 3. Black dots are genes not
differentially expressed.
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with HLSCs at week 2 (sacrificed at week 4), and in 4 out of
11 NASH mice injected at week 1 (sacrificed at week 4)
(Figure 8(a)). This therefore indicates the successful
engraftment of HLSCs in treated mice for up to 3 weeks
(Figure 8(a)). Immunofluorescence staining with an antibody
against HLA-class I showed the presence of human cells in
mice injected at different time points and sacrificed at week
4 (Figure 8(b)). HLA-1+ cells were observed to be widely
spread in the hepatic tissue (Figure 8(b)). Furthermore, they
did not coexpress markers of hepatic differentiation such
as cytokeratin-8 and cytokeratin-18 or albumin (data not
shown), suggesting that undifferentiated HLSCs persisted
in the liver parenchyma. No HLSC localization was
observed in healthy mice injected with cells (not shown)
or in mice with liver damage that were injected with vehicle
alone. This data therefore confirms the molecular analyses
done above.
4. Discussion
Cell therapy is regarded as a feasible alternative to whole
organ transplantation for the treatment of end-stage liver
diseases. A shortage in donor organs for the isolation of
human hepatocytes in sufficient quantity has increased the
need to find alternative cell sources such as stem/progenitor
cells. HLSCs are a stem cell population that are easily obtain-
able from human adult liver biopsies [8]. HLSCs express
many surface markers in common with hMSCs and embry-
onic and hepatic cells. Moreover, HLSCs were negative for
the expression of cytokeratin-19, a marker of oval cells, and
for alpha-SMA, a marker of activated stellate cells. At vari-
ance, adult-derived human liver mesenchymal-like cells
described by Najimi et al. [22] expressed α-Sma and cytoker-
atin-19, have CyP3A4 activity in the basal condition, and
secrete urea suggesting a more differentiated stage in respect
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Figure 4: Effect of HLSC injection on liver function of MCDD-fed mice. Aspartate aminotransferase (AST) (a), alanine aminotransferase
(ALT) (b) expressed as U/l, and albumin (c) expressed as g/dl were measured as biomarkers of liver cell injury in serum of control SCID
mice (CTRL), in mice fed with MCDD for 4 weeks and injected with vehicle alone (NASH), and in MCDD-fed mice treated with
intravenous injection of 1 5 × 106 HLSCs at week 1 (Group 1, n = 11), 2 (Group 2, n = 9), or 3 (Group 3, n = 9) and sacrificed at week 4.
Data are expressed as mean ± standard deviation (SD). ANOVA with Newman-Keuls multicomparison test was performed; ∗p < 0 05
HLSC-treated mice versus NASH mice.
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Figure 5: Effects of HLSCs on liver morphology and fibrosis. (a) Representative light microscopy micrographs of liver histology of mice at
week 4 of MCDD, treated with intravenous injection of 1 5 × 106 HLSCs or with vehicle alone (NASH) (original magnification 400x).
Sirius Red staining showed fibrosis in the perivenous area of MCDD-fed mice. Red stain represents collagen fibers considered to be a
marker of liver fibrosis. (b) Histological quantification of fibrosis in MCDD-fed mice injected with HLSCs or with vehicle alone (NASH)
at different weeks, by multiphase image analyses of 10 fields per section (original magnification 400x). Data shown represents mean ± SD.
ANOVA with Newman-Keuls multicomparison test was performed: ∗p < 0 05 MCDD-fed mice injected with 1 5 × 106 HLSCs at different
weeks (1 n = 11, 2 n = 9, or 3 n = 9) versus MCDD-fed mice injected with vehicle alone (NASH). (c) Histological quantification of the
surface area occupied by steatosis vacuoles in MCDD-fed mice injected with HLSCs or with vehicle alone (NASH) at different weeks
(1 n = 11, 2 n = 9, or 3 n = 9) by multiphase image analyses of 10 fields per section (original magnification 200x). Data shown represents
mean ± SD. (d) Quantification of PCNA-positive cells/high-power field (HPF) (original magnification ×400) in 10 fields per section. Data
represents mean ± SD. ANOVA with the Newman-Keuls multicomparison test was performed: ∗p < 0 05 MCDD-fed mice injected with
1 5 × 106 HLSCs at different weeks (1 n = 11, 2 n = 9, or 3 n = 9) versus MCDD-fed mice injected with vehicle alone (NASH). (e) Gene
expression levels of fibrotic markers Tgf-β, Col 1a1, and α-Sma in livers of MCDD-fed mice treated with vehicle alone or with HLSCs
(1 5 × 106) at different weeks (1 n = 11, 2 n = 9, or 3 n = 9). Data are expressed as relative quantification using the ΔΔCt method.
Normalization was made using GAPDH as a housekeeping gene. ANOVA with the Newman-Keuls multicomparison test was performed;
∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 HLSC-treated mice versus NASH mice treated with vehicle alone; #p < 0 05 MCDD-fed mice
NASH treated with vehicle alone versus control animals fed with standard diet.
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Figure 6: Effects of different amounts of HLSCs on liver function andmorphology inMCDD-fedmice. (a) Histological quantification of fibrosis in
MCDD-fedmice injected with different amounts of HLSCs (0.5, 1.5, or 3 × 106 and n = 6, 9, and 8, respectively) or with vehicle alone at week 2, by
multiphase image analyses of 10 fields per section (original magnification 400x). Data represents mean ± SD. ANOVA with the Newman-Keuls
multicomparison test was performed: ∗p < 0 05 MCDD-fed mice injected with different doses of HLSCs versus MCDD-fed mice injected with
vehicle alone (NASH). (b) Histological quantification of the surface area occupied by steatosis vacuoles in MCDD-fed mice injected with
different amounts of HLSCs (0.5, 1.5, or 3 × 106 and n = 6, 9, and 8, respectively) or with vehicle alone at week 2, by multiphase image analyses
of 10 fields per section (original magnification 200x). Data represents mean ± SD. Albumin (c), alanine aminotransferase (ALT) (d), aspartate
aminotransferase (AST) (e), and blood urea nitrogen (BUN) (f) were measured in the serum of control SCID mice (CTRL), in mice fed with
MCDD for 4 weeks and injected with vehicle alone (NASH), and in MCDD-fed mice treated with intravenous injection of different amounts of
HLSCs (0.5, 1.5, or 3 × 106 and n = 6, 9, and 8, respectively) at week 2 and sacrificed at week 4. Data are expressed as mean ± SD. ANOVA
with the Newman-Keuls multicomparison test was performed; ∗p < 0 05 HLSC-treated mice versus NASH mice treated with vehicle alone.
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to HLSCs, which expressed CyP3A4 activity and secrete urea
only after differentiation in hypogravity condition [8, 10].
HLSCs in an undifferentiated state have a great potential
to proliferate and remain stable for over seventeen culture
passages, as demonstrated by telomere length and gene
expression stability. Furthermore, we have confirmed that
HLSCs exhibit a similar phenotype and gene expression
profile to MSCs. At the same time, they also maintain a spe-
cific commitment towards a hepatic phenotype. In addition,
GMP protocols in order to obtain and expand HLSCs have
been established in our laboratory. Moreover, they have
been approved by the Italian Regulatory Agency for a phase
I study on urea cycle disorders (phase 1 study EudraCT:
2012-002120-33).
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Figure 7: Effects of HLSCs on liver inflammation. (a) Gene expression levels of proinflammatory cytokines Tnf-α, Il-1β, and Ifn-γ in livers of
MCDD-fed mice treated at different weeks (1 n = 11, 2 n = 9, or 3 n = 9) with 1 5 × 106 HLSCs or with vehicle alone. Data are expressed as
relative quantification using the ΔΔCt method. Normalization was made using GAPDH as a housekeeping gene. ANOVA with the
Newman-Keuls multicomparison test was performed; ∗p < 0 05 HLSC-treated mice versus NASH mice treated with vehicle alone and
#p < 0 05 MCDD-fed mice versus CTRL mice treated with standard diet. (b) Representative micrographs of liver cryosections from
MCDD-fed mice injected or not with HLSCs at week 1, 2, or 3, stained for CD45 to identify the presence of inflammatory cells. Infiltrates
of inflammatory cells. CD45-positive cells (green) were present only in MCDD-fed mice that did not receive cell treatment. Nuclei were
counter-stained with DAPI (blue). Original magnification 400x. Quantification of CD45-positive cells (c) and of FSP1-positive cells (d) per
HPF (original magnification ×400) in 10 fields per section. Data represents mean ± SD. ANOVA with the Newman-Keuls multicomparison
test was performed: ∗p < 0 05 MCDD-fed mice (NASH) treated with vehicle alone versusMCDD-fed mice injected with 1 5 × 106 HLSCs at
different weeks.
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Figure 8: HLSC engraftment in MCDD-fed mice. (a) Whole genome DNA analysis (α-sat-ch-17) of mouse livers sacrificed at week 4 of
MCDD and injected with HLSCs at week 1, 2, or 3. Ctrl+: positive control using HLSCs; Ctrl-: H2O. (b) Representative confocal
micrographs showing the presence of human cells localized widely in the liver parenchyma of MCDD-fed mice injected with vehicle alone
(NASH CTRL) or with 1 5 × 106 HLSCs at week 1, 2, or 3, as evaluated by HLA-class I (green). Costaining of murine cytokeratin-8 (red)
and HLA-class I (green) at week 3 is shown. Nuclei were counter-stained with DAPI (blue). Original magnification 400x. Arrows
indicate HLA-class I-positive cells.
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In the present study, we have shown that HLSCs may
exhibit a therapeutic potential in a MCDD-fed mouse model
of NASH. Mice maintained in MCDD developed steatosis,
accompanied by fibrosis and inflammation, which are con-
sidered the main features of NASH. Administration of
HLSCs ameliorated fibrosis and inflammation as observed
through histology and molecular analyses. In addition,
markers of liver function, such as ALT, AST, and plasma
albumin levels, were also restored to near normal levels.
Different time points of HLSC injection in NASH mice have
been tested, showing that early (week 1) and late (week 2
and 3) points of HLSC administration induced a significant
improvement of liver function and morphology, at histolog-
ical and molecular levels. Moreover, we tested different doses
of HLSCs, injected at week 2. All the cell doses tested induced
an amelioration of liver morphology, in particular of liver
fibrosis. In regard to liver function, injection of 1 5 × 106
HLSCs restored also serum albumin and only injection of a
higher dose (3 × 106 HLSCs) allowed an improvement of
the BUN level.
Notably, as HLSCs are committed to a hepatic lineage,
they do not require in vitro differentiation steps like bone
marrow MSC and induced pluripotent stem cells in order
to obtain beneficial effects in MCDD-fed mice [5–7].
To determine whether the improvement of NASH
observed post-HLSC administration was related to the
recruitment and engraftment of donor cells into the liver of
the recipients, we evaluated the presence of human cells in
HLSC-treated livers of mice, through histological and molec-
ular analyses. Our data showed that human cells persisted
up to 3 weeks in the liver of MCDD-fed mice. We have
previously shown that HLSCs are able to engraft and contrib-
ute to hepatic regeneration in an acute liver injury model
induced by N-acetyl-p-aminophenol [8]. Moreover, in a
lethal model of liver injury, induced by D-galactosamine
and lipopolysaccharide, HLSCs increased survival and were
engrafted in the liver parenchyma. Furthermore, a small pop-
ulation of HLSCs coexpressed cytokeratin-8 and cytokeratin-
18, seven days after injection, indicating a differentiation of
HLSCs into hepatocytes [12]. Nonetheless, after 21 days, an
undifferentiated population of HLSCs still persisted [12]. In
the present study, several human cells detected in the liver
parenchyma of MCDD-fed mice lacked the expression of
specific markers of hepatic differentiation, suggesting the
persistence of undifferentiated HLSCs. These data therefore
indicate that differentiation of HLSCs into mature hepato-
cytes was not necessary to attenuate liver fibrosis and inflam-
mation in this model.
A key factor in NASH is inflammation characterized by
the infiltration of inflammatory cells and increased expres-
sion of proinflammatory cytokines in the hepatic tissue.
Treatment with HLSCs alleviated liver inflammation in
MCDD-fed mice, through the reduction in levels of proin-
flammatory cytokines, as has also been described in different
animal models, whereby the local downregulation of proin-
flammatory cytokines is associated with tissue protection
and regeneration [23, 24]. Furthermore, the reduction in leu-
kocyte infiltration observed in MCDD-fed mice treated with
HLSCs could explain the reduction in fibrosis development,
since infiltrating macrophages play a pivotal role in the fibro-
genic process [25–27].
A hallmark of NASH-associated fibrosis is the activation
of hepatic stellate cells that is characterized by an increase in
α-SMA expression and collagen I deposition [28]. The levels
of both markers were significantly increased in the liver of
MCDD-fed mice and returned to near normal levels post-
treatment with HLSCs. These data therefore indicate that
the injection of HLSCs attenuated hepatic stellate cell activa-
tion. HLSCs could therefore influence directly the activation
state of stellate cells or indirectly through the reduction of the
hepatic inflammatory state. Moreover, TGF-β1 is considered
a major driver of fibrosis [29] and plays a pivotal role in
hepatic stellate cell activation [30, 31]. A remarkable achieve-
ment of our study is that HLSCs injected at different time
points significantly reduced the expression level of TGF-β
confirming the antifibrotic action of HLSCs.
HLSCs exerted their beneficial effect, at least in part, by
reducing the expression of profibrogenic factors, as has also
been shown for other stem cell types in different models of
liver fibrosis [31–35]. The hepatic growth factor (HGF) is a
well-known antifibrotic factor, and its role to ameliorate
fibrosis and inflammation has been reported in various
experimental models of NASH [36–38]. Furthermore, dele-
tion of the HGF-receptor c-met leads to the development of
severe NASH in mice [38]. Molecular analyses of HLSCs
revealed the expression of HGF mRNA in high levels. The
beneficial effect of HLSCs in the lethal model of acute liver
failure depended, at least in part, on HGF production [12].
We therefore speculate that in the MCDD-fed model of
NASH, HGF could play a relevant role in the beneficial
effects observed when administering HLSCs.
5. Conclusion
Taken together, these results demonstrated the healing
properties of HLSCs in a model of chronic liver disease.
In fact, treatment with HLSCs exhibited not only antifibro-
tic effects but also anti-inflammatory effects in a murine
model of NASH. Furthermore, these effects observed could
be attributed to the downregulation of profibrotic and pro-
inflammatory genes.
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